ES2531002T3 - Compuestos inhibidores de quinasa - Google Patents
Compuestos inhibidores de quinasa Download PDFInfo
- Publication number
- ES2531002T3 ES2531002T3 ES08724621T ES08724621T ES2531002T3 ES 2531002 T3 ES2531002 T3 ES 2531002T3 ES 08724621 T ES08724621 T ES 08724621T ES 08724621 T ES08724621 T ES 08724621T ES 2531002 T3 ES2531002 T3 ES 2531002T3
- Authority
- ES
- Spain
- Prior art keywords
- nr15r16
- heterocyclyl
- heteroaryl
- cycloalkyl
- aryl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/63—One oxygen atom
- C07D213/65—One oxygen atom attached in position 3 or 5
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
- C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D237/22—Nitrogen and oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Un compuesto de fórmula II:**Fórmula** o una sal, un hidrato o un solvato del mismo; en la que: R1 es arilalquilo o heteroarilalquilo, cada uno opcionalmente sustituido con 1-4 Z1 independientes; R2 es arilo, heteroarilo, heterociclilo o -C(O)NH2, cada uno opcionalmente sustituido con 1-4 Z2 independientes; R3 es hidrógeno, hidroxilo, alcoxi o alquilamino; R5 es hidrógeno, NH2 o CH3; Cada Z1 y Z2 es independientemente halógeno, CN, NO2, OR15, SR15, S(O)2OR15, NR15R16, perfluoroalquilo C1- C2, perfluoroalcoxi C1-C2, metilendioxi, C(O)OR15, C(O)NR15R16, OC(O)NR15R16, NR15C(O)NR15R16, C(NR16)NR15R16, NR15C(NR16)NR15R16, S(O)2NR15R16, R17, C(O)R17, NR15C(O)R17, S(O)R17, S(O)2R17, R16, oxo, C(O)R16, C(O)(CH2)nOH, (CH2)nOR15, (CH2)nC(O)NR15R16, NR15S(O)2R17, en los que n es independientemente 0- 6 inclusive; Cada R15 es independientemente hidrógeno, alquilo C1-C4 o cicloalquilo C3-C6; Cada R16 es independientemente hidrógeno, alquenilo, alquinilo, cicloalquilo C3-C6, arilo, heterociclilo, heteroarilo, alquilo C1-C4 o alquilo C1-C4 sustituido con cicloalquilo C3-C6, arilo, heterociclilo o heteroarilo; y Cada R17 es independientemente cicloalquilo C3-C6, arilo, heterociclilo, heteroarilo, alquilo C1-C4 o alquilo C1-C4 sustituido con cicloalquilo C3-C6, arilo, heterociclilo o heteroarilo.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US88179207P | 2007-01-19 | 2007-01-19 | |
| US88179107P | 2007-01-19 | 2007-01-19 | |
| PCT/US2008/000694 WO2008088881A1 (en) | 2007-01-19 | 2008-01-18 | Kinase inhibitor compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2531002T3 true ES2531002T3 (es) | 2015-03-09 |
Family
ID=39636312
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES08724621T Active ES2531002T3 (es) | 2007-01-19 | 2008-01-18 | Compuestos inhibidores de quinasa |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US8551995B2 (es) |
| EP (1) | EP2120578B1 (es) |
| JP (1) | JP2010516680A (es) |
| CA (1) | CA2675755C (es) |
| ES (1) | ES2531002T3 (es) |
| WO (1) | WO2008088881A1 (es) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BRPI0914305B8 (pt) * | 2008-06-19 | 2021-05-25 | Xcovery Holding Co Llc | compostos de piridazina carboxamida substituída como compostos inibidores da quinase, uso dos compostos e uso de uma composição compreendendo os compostos |
| EP2356116A1 (en) * | 2008-11-20 | 2011-08-17 | OSI Pharmaceuticals, Inc. | Substituted pyrroloý2,3-b¨-pyridines and-pyrazines |
| EP2566858A2 (en) * | 2010-05-04 | 2013-03-13 | Pfizer Inc. | Heterocyclic derivatives as alk inhibitors |
| AR081039A1 (es) | 2010-05-14 | 2012-05-30 | Osi Pharmaceuticals Llc | Inhibidores biciclicos fusionados de quinasa |
| JP2013526570A (ja) | 2010-05-14 | 2013-06-24 | オーエスアイ・ファーマシューティカルズ,エルエルシー | 縮合二環式キナーゼ阻害剤 |
| ES2715611T3 (es) | 2010-05-17 | 2019-06-05 | Incozen Therapeutics Pvt Ltd | Compuestos novedosos de 3H-imidazo[4,5-b]piridina-3,5-disustituida y 3H-[1,2,3]triazolo[4,5-b]piridina 3,5-disustituida como moduladores de proteína cinasas |
| EP2585455B1 (en) | 2010-06-24 | 2019-08-07 | The Regents of the University of California | Compounds and uses thereof in modulating levels of various amyloid beta peptide alloforms |
| EP2588107A1 (en) | 2010-07-01 | 2013-05-08 | Takeda Pharmaceutical Company Limited | COMBINATION OF A cMET INHIBITOR AND AN ANTIBODY TO HGF AND/OR cMET |
| PL2625176T3 (pl) * | 2010-10-08 | 2017-08-31 | Xcovery Holding Company Llc | Podstawione związki 6-amino-pirydazyn-3-ylo-karboksyamidu jako modulatory kinazy białkowej |
| CN103298803A (zh) * | 2010-10-08 | 2013-09-11 | 艾科睿控股公司 | 作为激酶抑制剂化合物的取代的哒嗪羧酰胺化合物 |
| LT2822953T (lt) | 2012-03-06 | 2017-04-10 | Pfizer Inc. | Makrocikliniai dariniai, skirti proliferacinių ligų gydymui |
| CN107082779A (zh) | 2012-03-30 | 2017-08-22 | 理森制药股份公司 | 作为c‑met 蛋白激酶调节剂的新化合物 |
| US9499561B2 (en) | 2012-04-10 | 2016-11-22 | Shanghai Yingli Pharmaceutical Co., Ltd. | Fused pyrimidine compound, and preparation method, intermediate, composition, and uses thereof |
| US9938263B2 (en) | 2013-03-12 | 2018-04-10 | The General Hospital Corporation | Gamma-secretase modulators |
| WO2014140073A1 (en) * | 2013-03-13 | 2014-09-18 | F. Hoffmann-La Roche Ag | Process for making benzoxazepin compounds |
| JP6672296B2 (ja) | 2014-10-31 | 2020-03-25 | ザ ジェネラル ホスピタル コーポレイション | 強力なγ−セクレターゼモジュレータ |
| CA2969268A1 (en) | 2014-12-02 | 2016-06-09 | Bayer Pharma Aktiengesellschaft | Heteroaryl-substituted imidazo[1,2-a]pyridines and their use |
| ES2764299T3 (es) | 2014-12-09 | 2020-06-02 | Inst Nat Sante Rech Med | Anticuerpos monoclonales humanos contra AXL |
| WO2016135041A1 (en) | 2015-02-26 | 2016-09-01 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Fusion proteins and antibodies comprising thereof for promoting apoptosis |
| CN112824387B (zh) * | 2019-11-21 | 2023-03-21 | 济南尚博生物科技有限公司 | 一种2-甲基烟酸酯及其制备方法和应用 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4369172A (en) | 1981-12-18 | 1983-01-18 | Forest Laboratories Inc. | Prolonged release therapeutic compositions based on hydroxypropylmethylcellulose |
| DE3583799D1 (de) | 1985-01-11 | 1991-09-19 | Abbott Lab Ltd | Feste zubereitung mit langsamer freisetzung. |
| JP2773959B2 (ja) | 1990-07-10 | 1998-07-09 | 信越化学工業株式会社 | 大腸内放出性固形製剤 |
| US5563158A (en) * | 1993-12-28 | 1996-10-08 | The Dupont Merck Pharmaceutical Company | Aromatic compounds containing basic and acidic termini useful as fibrinogen receptor antagonists |
| UA73092C2 (uk) | 1998-07-17 | 2005-06-15 | Брістол-Майерс Сквібб Компані | Таблетка з ентеросолюбільним покриттям і спосіб її приготування |
| EP1101490B1 (en) | 1998-07-28 | 2005-04-13 | Tanabe Seiyaku Co., Ltd. | Preparation capable of releasing drug at target site in intestine |
| US6461631B1 (en) | 1999-11-16 | 2002-10-08 | Atrix Laboratories, Inc. | Biodegradable polymer composition |
| EP2264014A1 (en) * | 2001-08-31 | 2010-12-22 | Université Louis Pasteur | Substituted pyridazines as anti-inflammatory agents and protein kinase inhibitors |
| CA2470214A1 (en) * | 2001-12-13 | 2003-06-26 | Abbott Laboratories | 3-(phenyl-alkoxy)-5-(phenyl)-pyridine derivatives and related compounds as kinase inhibitors for the treatment of cancer |
| US7015227B2 (en) * | 2002-06-21 | 2006-03-21 | Cgi Pharmaceuticals, Inc. | Certain amino-substituted monocycles as kinase modulators |
| US6800663B2 (en) | 2002-10-18 | 2004-10-05 | Alkermes Controlled Therapeutics Inc. Ii, | Crosslinked hydrogel copolymers |
| GEP20084341B (en) | 2003-02-26 | 2008-03-25 | Sugen Inc | Aminoheteroaryl compounds as protein kinase inhibitors |
| EP2392565B1 (en) * | 2003-09-26 | 2014-03-19 | Exelixis, Inc. | c-Met modulators and methods of use |
| EP1720855A4 (en) * | 2004-03-02 | 2008-12-17 | Smithkline Beecham Corp | HEMMER OF ACT ACTIVITY |
| BRPI0513915A (pt) * | 2004-08-26 | 2008-05-20 | Pfizer | compostos aminoeteroarila enantiomericamente puros como inibidores de proteìna quinase |
| NZ552946A (en) | 2004-08-26 | 2010-09-30 | Pfizer | Pyrazole-substituted aminoheteroaryl compounds as protein kinase inhibitors |
| WO2006021886A1 (en) | 2004-08-26 | 2006-03-02 | Pfizer Inc. | Aminoheteroaryl compounds as protein tyrosine kinase inhibitors |
| WO2006114180A1 (de) * | 2005-04-25 | 2006-11-02 | Merck Patent Gmbh | Neuartige aza-heterozyklen als kinase-inhibitoren |
-
2008
- 2008-01-18 CA CA2675755A patent/CA2675755C/en active Active
- 2008-01-18 EP EP08724621.1A patent/EP2120578B1/en active Active
- 2008-01-18 JP JP2009546432A patent/JP2010516680A/ja active Pending
- 2008-01-18 US US12/523,469 patent/US8551995B2/en active Active
- 2008-01-18 WO PCT/US2008/000694 patent/WO2008088881A1/en not_active Ceased
- 2008-01-18 ES ES08724621T patent/ES2531002T3/es active Active
Also Published As
| Publication number | Publication date |
|---|---|
| HK1137295A1 (en) | 2010-07-30 |
| US20100063031A1 (en) | 2010-03-11 |
| EP2120578A4 (en) | 2013-01-30 |
| EP2120578A1 (en) | 2009-11-25 |
| US8551995B2 (en) | 2013-10-08 |
| JP2010516680A (ja) | 2010-05-20 |
| EP2120578B1 (en) | 2014-11-19 |
| WO2008088881A1 (en) | 2008-07-24 |
| CA2675755A1 (en) | 2008-07-24 |
| CA2675755C (en) | 2015-10-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2531002T3 (es) | Compuestos inhibidores de quinasa | |
| ES2564782T3 (es) | Compuestos derivados de 1-aril-5-alquil pirazol, procedimientos de fabricación y procedimientos de utilización de los mismos | |
| CO6210770A2 (es) | Compuestos 2-aril-5-heterociclil-ciclohexan-1, 3 diona y su uso como herbicidas | |
| CO6220935A2 (es) | Derivados de 1,2,4-triazol como moduladores de mglur5 | |
| NO20073956L (no) | Pyrazolderivater for inhibering av CDK og GSK | |
| AR061642A1 (es) | Derivados de ureas de tropano, su preparacion y su aplicacion en terapeu-tica, procesos de obtencion y composiciones farmaceuticas | |
| PY1030698A (es) | Mezclas pesticidas mesoionicos | |
| PE20131165A1 (es) | Analogos de carba-nucleosidos sustituidos con 2'-fluoro para tratamiento antiviral | |
| PE20140171A1 (es) | Pirazoles fungicidas y sus mezclas | |
| AR060506A1 (es) | Compuestos organicos | |
| AR077977A1 (es) | Compuestos y composiciones como inhibidores de cinasa de proteina | |
| EA201170096A1 (ru) | Замещенные производные пиримидона | |
| NO20074057L (no) | 2,4-Diaminopyridopyrimidinderivater og deres anvendelse som mTOR-inhibitorer | |
| PE20090630A1 (es) | Derivados de indol 2-carboxi sustituidos y metodos para su utilizacion | |
| AR056536A1 (es) | Compuestos de 2-amino-5- [4-(difluormetoxi)fenil]-5-fenilimidazolona como inhibidores de la beta secretasa (bace) | |
| ATE524765T1 (de) | Fotoaktivierbare stickstoffbasen | |
| PE20071285A1 (es) | Composicion para inducir la tolerancia de plantas contra bacteriosis | |
| UY30897A1 (es) | Derivados de pentafluorotiobenzamidoacetonitrilo, composiciones conteniéndolos y aplicaciones | |
| CO6150142A2 (es) | Bezoxazoles y oxazolopiridinas que son utiles como inhibidores de las cinasas janus | |
| AR067058A1 (es) | Oxazolidinonas sustituidas y su uso para preparar medicamentos | |
| AR079498A1 (es) | Derivados de 2-arilimidazol heteroaromaticos como inhibidores de enzima pde10a | |
| CO6260132A2 (es) | Derivados de oxadiazol como inhibidores de dgat | |
| NO20071008L (no) | Fremgangsmate for fremstilling av N-piperidino-1,5-difenylpyrazol-3-karboksamidderivater | |
| CO6160220A2 (es) | Proceso e intermediarios para la sintesis de derivados de 2-(quinolin-5-il)-4,5-azol-disustituido | |
| ATE480239T1 (de) | Angiogeneseinhibitoren |